{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:21:20Z","timestamp":1787023280102,"version":"build-2736575974"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,9,1]]},"abstract":"<jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After completing this course, the reader will be able to: Appraise the available data supporting the use of autologous stem cell transplant in follicular lymphoma, mantle cell lymphoma, and peripheral T-cell lymphoma.Discuss the appropriate role of autologous stem cell transplant in the treatment of follicular lymphoma, mantle cell lymphoma, and peripheral T-cell lymphoma.Outline the areas of investigation regarding mobilization, conditioning, and maintenance regimens for autologous stem cell transplant in follicular lymphoma, mantle cell lymphoma, and peripheral T-cell lymphoma.<\/jats:p>\n                  <jats:p>This article is available for continuing medical education credit at CME.TheOncologist.com<\/jats:p>","DOI":"10.1634\/theoncologist.2009-0162","type":"journal-article","created":{"date-parts":[[2009,9,8]],"date-time":"2009-09-08T22:08:18Z","timestamp":1252447698000},"page":"921-929","source":"Crossref","is-referenced-by-count":20,"title":["Controversies in the Treatment of Lymphoma with Autologous Transplantation"],"prefix":"10.1093","volume":"14","author":[{"given":"Alison J.","family":"Moskowitz","sequence":"first","affiliation":[{"name":"Lymphoma Service, Memorial-Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig H.","family":"Moskowitz","sequence":"additional","affiliation":[{"name":"Lymphoma Service, Memorial-Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,9,8]]},"reference":[{"key":"2021122207231579200_R1","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"2021122207231579200_R2","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: Results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"2021122207231579200_R3","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: A randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"2021122207231579200_R4","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin\u2019s lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin\u2019s Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122207231579200_R5","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","article-title":"Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center","volume":"13","author":"Johnson","year":"1995","journal-title":"J Clin Oncol"},{"key":"2021122207231579200_R6","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1038\/sj.leu.2404850","article-title":"Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: An EBMT registry study","volume":"21","author":"Montoto","year":"2007","journal-title":"Leukemia"},{"key":"2021122207231579200_R7","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","article-title":"Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: The GELF-94 randomized study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA)","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"key":"2021122207231579200_R8","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"2021122207231579200_R9","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2008-05-160200","article-title":"High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years","volume":"113","author":"Gyan","year":"2009","journal-title":"Blood"},{"key":"2021122207231579200_R10","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","article-title":"Prospective, multicenter randomized GITMO\/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: The superior disease control of R-HDS does not translate into an overall survival advantage","volume":"111","author":"Ladetto","year":"2008","journal-title":"Blood"},{"key":"2021122207231579200_R11","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: Results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122207231579200_R12","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","article-title":"Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: Long-term follow-up","volume":"25","author":"Rohatiner","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122207231579200_R13","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/blood.V86.8.3257.3257","article-title":"Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma","volume":"86","author":"Bastion","year":"1995","journal-title":"Blood"},{"key":"2021122207231579200_R14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bbmt.2007.06.016","article-title":"Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: Effect of histological grade and Follicular International Prognostic Index","volume":"14","author":"Vose","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122207231579200_R15","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","article-title":"New treatment options have changed the survival of patients with follicular lymphoma","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122207231579200_R16","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/sj.bmt.1705849","article-title":"Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma","volume":"40","author":"Kang","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"2021122207231579200_R17","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/bmt.2008.382","article-title":"Rituximab purging and maintenance combined with auto-SCT: Long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma","volume":"43","author":"Hicks","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"2021122207231579200_R18","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/annonc\/mdg200","article-title":"Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin\u2019s lymphoma","volume":"14","author":"Hosing","year":"2003","journal-title":"Ann Oncol"},{"key":"2021122207231579200_R19","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"key":"2021122207231579200_R20","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1038\/sj.leu.2404822","article-title":"Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: Pre-transplant disease status and histotype heavily influence outcome","volume":"21","author":"Corradini","year":"2007","journal-title":"Leukemia"},{"key":"2021122207231579200_R21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122207231579200_R22","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"issue":"suppl 4","key":"2021122207231579200_R23","first-page":"iv86","article-title":"Results of sequential chemotherapy followed by high dose therapy and autologous stem cell rescue for mantle cell lymphoma: Role of rituximab and functional imaging","volume":"19","author":"Zelenetz","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122207231579200_R24","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"2021122207231579200_R25","first-page":"1275","article-title":"Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: An update of a prospective study","volume":"89","author":"Lefr\u00e8re","year":"2004","journal-title":"Haematologica"},{"key":"2021122207231579200_R26","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood.V112.11.833.833","article-title":"Rituximab (R) + hypercvad alternating with R-methotrexate\/cytarabine after 9 years: Continued high rate of failure-free survival in untreated mantle cell lymphoma (MCL). ASH Annual Meeting Abstracts","volume":"112","author":"Romaguera","year":"2008","journal-title":"Blood"},{"key":"2021122207231579200_R27","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122207231579200_R28","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","article-title":"Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)","volume":"102","author":"Gianni","year":"2003","journal-title":"Blood"},{"key":"2021122207231579200_R29","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/bmt.2008.349","article-title":"High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: A 10-year update of the R-HDS regimen","volume":"43","author":"Magni","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"2021122207231579200_R30","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1182\/blood.V110.11.1281.1281","article-title":"Successful preemptive treatment of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. ASH Annual Meeting Abstracts","volume":"110","author":"Andersen","year":"2007","journal-title":"Blood"},{"key":"2021122207231579200_R31","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2141.2003.04140.x","article-title":"Outcome of autologous transplantation for mantle cell lymphoma: A study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries","volume":"120","author":"Vandenberghe","year":"2003","journal-title":"Br J Haematol"},{"key":"2021122207231579200_R32","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":"Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"2021122207231579200_R33","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207231579200_R34","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: Results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122207231579200_R35","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"key":"2021122207231579200_R36","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"Mercadal","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122207231579200_R37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","article-title":"Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: A prospective study from The Gel-Tamo Study Group","volume":"79","author":"Rodr\u00edguez","year":"2007","journal-title":"Eur J Haematol"},{"key":"2021122207231579200_R38","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbmt.2008.04.004","article-title":"Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: The Stanford experience","volume":"14","author":"Chen","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122207231579200_R39","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.bbmt.2008.11.010","article-title":"Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: Complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome","volume":"15","author":"Yang","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122207231579200_R40","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/sj.bmt.1705752","article-title":"The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: A BSBMT and ABMTRR study","volume":"40","author":"Feyler","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"2021122207231579200_R41","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-007-0254-1","article-title":"High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: Complete response at transplant predicts survival","volume":"86","author":"Kim","year":"2007","journal-title":"Ann Hematol"},{"key":"2021122207231579200_R42","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2001.19.17.3766","article-title":"Impact of high-dose chemotherapy on peripheral T-cell lymphomas","volume":"19","author":"Rodriguez","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122207231579200_R43","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin\u2019s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122207231579200_R44","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","article-title":"Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma","volume":"94","author":"Freedman","year":"1999","journal-title":"Blood"},{"key":"2021122207231579200_R45","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1182\/blood.V108.11.2737.2737","article-title":"Immuno-chemotherapy (IC) and autologous stem cell transplant (ASCT) for untreated patients (pts) with mantle cell lymphoma (MCL): CALGB 59909. ASH Annual Meeting Abstracts","volume":"108","author":"Damon","year":"2006","journal-title":"Blood"},{"key":"2021122207231579200_R46","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2006.06164.x","article-title":"Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma","volume":"134","author":"Kewalramani","year":"2006","journal-title":"Br J Haematol"},{"key":"2021122207231579200_R47","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.11173","article-title":"The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing\/refractory peripheral T-cell lymphoma","volume":"92","author":"Rodr\u00edguez","year":"2007","journal-title":"Haematologica"},{"key":"2021122207231579200_R48","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1182\/blood.V108.11.3060.3060","article-title":"The impact of disease status on the outcome of high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) for peripheral T-cell lymphoma (PTCL). ASH Annual Meeting Abstracts","volume":"108","author":"Nademanee","year":"2006","journal-title":"Blood"},{"key":"2021122207231579200_R49","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1080\/10428190412331272749","article-title":"Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant","volume":"45","author":"Jagasia","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"2021122207231579200_R50","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.bmt.1702867","article-title":"High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas","volume":"27","author":"Blystad","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"2021122207231579200_R51","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1046\/j.1365-2141.2003.04203.x","article-title":"Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: Variable outcome according to pathological subtype","volume":"120","author":"Song","year":"2003","journal-title":"Br J Haematol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2009-0162","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2009-0162","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/14\/9\/921\/41841472\/oncolo_14_9_921.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/14\/9\/921\/41841472\/oncolo_14_9_921.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T02:51:45Z","timestamp":1640141505000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/14\/9\/921\/6398070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,1]]},"references-count":51,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2009,9,8]]},"published-print":{"date-parts":[[2009,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2009-0162","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,9,1]]},"published":{"date-parts":[[2009,9,1]]}}}